期刊文献+

结直肠癌组织中HMGN5表达及其临床意义 被引量:5

Analysis of HMGN5 expression in colorectal cancer tissues and its clinical significance
下载PDF
导出
摘要 目的探讨结直肠癌组织中高迁移率族核小体结合域5(HMGN5)的水平及其临床意义。方法收集眉山市人民医院2005年4月至2010年10月手术切除的176例结直肠癌组织和78例癌旁正常组织,采用免疫组化检测以上组织中HMGN5的表达水平,比较结直肠癌组织及癌旁正常组织中的HMGN5阳性表达率,分析结直肠癌组织HMGN5阳性表达率与临床病理特征(性别、年龄、肿瘤位置、病理分级、TNM分期和肿瘤大小)的关系,根据随访资料分析不同HMGN5表达水平与预后的关系。结果免疫组化结果显示结直肠癌组织的HMGN5阳性表达率为68.75%(121/176),高于癌旁组织的26.92%(21/78),差异有统计学意义(P<0.05);结直肠癌组织HMGN5阳性表达率与年龄、性别、肿瘤位置、病理分级和肿瘤大小均无关,与TNM分期有关,其中Ⅲ、Ⅳ期组织的HMGN5阳性表达率为81.05%(77/95),高于Ⅰ、Ⅱ期的54.32%(44/81),差异有统计学意义(P<0.05)。HMGN5阴性表达者的中位生存期为56.0个月,长于阳性表达者的37.0个月(P<0.05)。结论 HMGN5在结直肠癌组织中的表达升高,且阳性表达者的预后较差、TNM分期较晚,可能与结直肠癌的发生发展有关,在结直肠癌诊断及病情评估有一定价值。 Objective To investigate the expression of high-mobility group nucleosome-binding domain 5(HMGN5)and its clinical significance in colorectal cancer tissues.Methods One hundred and seventy-six cases of colorectal cancer tissues and 78 cases of adjacent normal tissues were collected in Meishan People s Hospital from April 2005 to October 2010.Immunohistochemistry was used to detect the expression of HMGN5 in the above tissues.The positive expression rates of HMGN5 in colorectal cancer tissues and adjacent normal tissues were compared.The relationship between the positive rates of HMGN5 and the clinicopathological parameters of colorectal cancer(sex,age,tumor location,pathological grade,TNM staging and tumor size)was analyzed.Besides,the relationship between HMGN5 expression and prognosis was analyzed based on follow-up data.Results The immunohistochemical results showed that the positive expression rate of HMGN5 in colorectal cancer tissues was 68.75%(121/176),higher than 26.92%(21/78)of adjacent normal tissues,and the difference was statistically significant(P<0.05).The positive expression rate of HMGN5 in colorectal cancer tissues was not related to age,sex,tumor location,pathological grade and tumor size,but related to TNM staging.The positive expression rate of HMGN5 in tissues ofⅢandⅣstage was 81.05%(77/95),higher than 54.32%(44/81)ofⅠandⅡstage,and the difference was statistically significant(P<0.05).The median overall survival of patients with HMGN5 negative expression was 56.0 months,longer than 37.0 months of patients with positive expression(P<0.05).Conclusion The elevated expression of HMGN5 in colorectal cancer tissues was associated with poor prognosis and advanced TNM stage.It may be related to the development of colorectal cancer,and it has some value in the diagnosis of colorectal cancer and the evaluation of the disease.
作者 邓先锐 万顷 伍洪彬 DENG Xianrui;WAN Qing;WU Hongbin(Department of Gastroenterological Surgery,Meishan People s Hospital,Meishan 620010,China)
出处 《临床肿瘤学杂志》 CAS 北大核心 2018年第6期533-536,共4页 Chinese Clinical Oncology
关键词 结直肠癌 高迁移率族核小体结合域5 临床意义 预后 Colorectal cancer High-mobility group nucleosome-binding domain 5 Clinical significance Prognosis
  • 相关文献

参考文献3

二级参考文献29

  • 1吴准,倪栋,闫永吉,李俊,王保军,欧阳金枝,张国玺,马鑫,李宏召,张旭.Expression of Angiotensin Ⅱ Receptors in Aldosterone-producing Adenoma of the Adrenal Gland and Their Clinical Significance[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(4):486-489. 被引量:4
  • 2Jae Yun Lim,Sun Och Yoon,So-Young Seol,Soon Won Hong,Jong Won Kim,Seung Ho Choi,Ju-Seog Lee,Jae Yong Cho.Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype[J].World Journal of Gastroenterology,2013,19(41):7078-7088. 被引量:11
  • 3Antti J. Kivela,Seppo Parkkila,Juha Saarnio,Tuomo J. Karttunen,Jyrki Kivela,Anna-Kaisa Parkkila,Maria Bartosova,Vojtech Mucha,Michal Novak,Abdul Waheed,William S. Sly,Hannu Rajaniemi,Silvia Pastorekova,Jaromir Pastorek.Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa[J].World Journal of Gastroenterology,2005,11(17):2616-2625. 被引量:10
  • 4Siegel R, Ward E, Brawley O, et al the impact of eliminating : Cancer statistics, 2011: e and racial disparities on premature cancer deaths [ J ]. CA Cancer J Clin, 2011, 61 (4) 212-236.
  • 5Cheng L, Eng C, Nieman LZ, et al. Trendsin colorectal cancer incidence by anatomic site and disease stage in the US from 1976 to 2005[J]. Am J Clin Oncol, 2011, 34(6) : 573-580.
  • 6Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer [ J ]. J Clin Oncol, 2008, 26(29) :4828-4833.
  • 7Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI, andfluoropyrimidines in metastatic colorectal cancer: the BEAT study [ J ]. Ann Oncol, 2009, 20 ( 11 ) : 1842-1847.
  • 8Adelstein BA, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of re- sponse to anti-EGFR antibodies and the impact of partner chemo- therapy in metastatic colorectal cancer[ J]. Eur J Cancer, 2011, 47(9) : 1343-1354.
  • 9Lin AY, Buckley NS, Lu AT, et al. Effect of KRAS mutational status in advanced eolorectal cancer on the outeomes of anti-epi- dermal growth factor receptor monoclonal antibody therapy : a sys- tematic review and meta-analysis [ J]. Clin Colorectal Cancer, 2011, 10(1) : 63-69.
  • 10Van Cutsem E, Kohne CH, Hitre E, et al.Cetuximab and chem- otherapy as initial treatment for metastatic colorectal cancer [ J ]. N Engl J Med, 2009, 360(14) : 1408-1417.

共引文献16

同被引文献36

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部